BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma ...
A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...
BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support ...
BridgeBio Pharma is back in focus after its fair value estimate was lifted from $89.79 to $100.05, an increase of about 11% that resets the conversation around upside and risk. That move aligns with ...
BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from ...
The company reiterated its goal of achieving "30-plus percent market share by volume in the years to come" for Attruby. Kumar stated, "The obvious growth in our portfolio today sits with the expansion ...
About Attruby™ (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in ...
Shares of BridgeBio PharmaBBIO are up more than 160% this year as the small biotech company takes on drug behemoths PfizerPFE and Alnylam PharmaceuticalsALNY. Though the company is just 10 years old, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results